These studies have because been validated by convergent findings, and there is a general consensus that tau burden in DLB is intermediate between healthy controls and AD, although the level of concomitant amyloid may be highly influential (Coughlin et al., 2020; Lee et al., 2018; Smith et al., 2018). The gene discussed is MAPT; the disease is Lewy body dementia.